June 12, 2026
A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and should pay $20.2 million in damages — the full amount Harbour was seeking.
June 04, 2026
A Delaware federal judge has trimmed Harbour Medical's infringement suit against an Amgen unit just days before trial, saying two of the company's mouse antibody patents are indefinite based on a term that "everyone agrees" is "nonsensical."
October 07, 2022
A special master in Delaware has recommended clearing DLA Piper to represent a Dutch developer of biomedical mice in the company's patent lawsuit against a rival recently purchased by Amgen, despite the BigLaw firm's ongoing work handling "environmental, social, and governance initiatives" for Amgen.